Entries by Max

UPDATE: Phase 1 Trial of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

/in , , /by

A new Phase 1 clinical study, known as the ARTISAN trial, is evaluating an investigational lead-212 alpha radioligand therapy targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). We discussed AB001 in a previous article; the trial has now been approved, and its full details are available. The therapy combines a […]

Newsletter 41/2025

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! ​First of all, thank you! The target has been reached. Thanks to your donations, I can renew our subscription to Kit.com and keep sending the newsletters!​ This week we have a great mix of clinical and preclinical research, including […]

Scientists Develop “Velcro” Cancer Treatment That Works Across Many Tumor Types

/in , /by

Researchers at the University of California, Irvine have developed an innovative cancer immunotherapy called GlyTR, a new class of treatment that uses a “velcro-like” mechanism to target sugar molecules abundantly present on cancer cells. Their findings were published in September 2025 in the prestigious journal Cell, marking a significant advancement in cancer immunotherapy. Traditional immunotherapies […]

New Study Uncovers Mechanism Behind T-Cell Exhaustion, Offering Hope for Prostate Cancer Immunotherapy

/in , /by

A study from The Ohio State University Comprehensive Cancer Center has illuminated a critical reason why cancer immunotherapy often fails: T-cell exhaustion driven by a novel stress pathway called TexPSR (proteotoxic stress response in T-cell exhaustion). Published in the prestigious journal Nature, this discovery reveals a proteotoxic shock in exhausted T cells caused by the […]